Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The proteogenomics landscape of non-small cell lung cancer
Proteogenomic analysis of patient-derived samples provides insights into the biology and molecular classification of non-small cell lung cancer and identifies potential cancer-cell intrinsic and immune vulnerabilities.
The mechanisms regulating the progression of benign tumors to malignant carcinomas remain incompletely understood. A new study identifies the transcription factor NR2F2 as a specific regulator of this transition that plays critical roles in the maintenance of the malignant tumor state.
Glioblastoma multiforme (GBM) is a lethal form of primary brain cancer. A new study now implicates beta-secretase 1 (BACE1) as a crucial regulator of pro-tumoral IL-6–STAT3 signaling in GBM-associated macrophages. An effective BACE1 inhibitor, clinically developed for Alzheimer’s disease, may offer new hope for GBM treatment.
Acute myeloid leukemia (AML) is a heterogeneous disease with limited therapeutic options. A new study identifies leukocyte immunoglobulin-like receptor 3 (LILRB3) as a marker of monocytic AML, with the ability to modulate NF-κB signaling and to promote survival and immune evasion. Blockade of LILRB3 signaling could provide a novel therapeutic strategy in monocytic AML.
Ting and colleagues report the safety and efficacy of combined radiation and immunotherapy in a phase II trial on patients with MSS colorectal or pancreatic cancer and observe that disease control correlates with higher repetitive RNA transcription.
Zhai et al. identify clinical brain-penetrant BACE1 inhibitors as regulators of macrophage-dependent phagocytosis in glioblastoma through IL-6–STAT3 signaling and demonstrate preclinical therapeutic efficacy in orthotopic mouse models and PDXs.
Blanpain and colleagues identify NR2F2 as a regulator of stemness and invasiveness that promotes tumor renewal and restricts differentiation to sustain squamous cell carcinomas.
Wu et al. show that LILRB3 modulates AML cell survival and antileukemic T-cell responses through regulation of TRAF2–cFLIP–NF-κB signaling and demonstrate the therapeutic efficacy of LILRB3-blocking antibodies in humanized PDX models in vivo.
Singh and colleagues show that PDAC phenotypic plasticity is regulated via AP1 enhancer remodeling and modulated by TNF-α+ macrophages and pharmacological inhibition of the BRD4–cJUN–CCL2–TNF-α axis restores favorable PDAC subtypes and prognosis.
Sarry and colleagues demonstrate that adaptive resistance to venetoclax + cytarabine therapy in acute myeloid leukemia relies on mitochondrial respiration and show that combination with electron transport chain complex inhibitors delays relapse in patient-derived xenograft models in vivo.
Lehtiö and colleagues perform proteogenomic analysis of non-small cell lung cancer and identify molecular subtypes with distinct immune-evasion mechanisms and therapeutic targets and validate their classification method in separate clinical cohorts.